Get the Stockscreener App
7.98
3.04%
-0.25
Upstream Bio Inc stock is traded at $7.98, with a volume of 138.47K.
It is down -3.04% in the last 24 hours and down -26.18% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases.
See More
Previous Close:
$8.23
Open:
$8.3
24h Volume:
138.47K
Relative Volume:
0.45
Market Cap:
$427.70M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-6.2116
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
+5.00%
1M Performance:
-26.18%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$7.875
$8.6023
1-Week Range:
$7.66
$8.735
52-Week Range:
$6.65
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
7.98 | 427.70M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Global Upstream Bioprocessing Equipment Market Poised for - GlobeNewswire
Upstream Bioprocessing Market Size to Reach $105.46 Bn by 2034 - BioSpace
Upstream Bio Inc (NASDAQ: UPB) – An Analysis Is What You Need - Stocks Register
‘It’s not for the faint of heart.’ How 3 CEOs took their biotechs public - BioPharma Dive
Critical Alert: Auto Industry Hit By Devastating Cyber Attacks60% Incidents Impact Millions - StockTitan
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week LowHere's Why - MarketBeat
Upstream Bio (NASDAQ:UPB) Trading Down 7.3%Here's What Happened - MarketBeat
Severe Asthma FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Trading 9.4% HigherStill a Buy? - MarketBeat
Upstream Bio (UPB) to Release Quarterly Earnings on Thursday - MarketBeat
Moody Aldrich Partners LLC Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB) - MarketBeat
Chronic Rhinosinusitis with Nasal Polyps Pipeline 2024: FDA - openPR
Upstream Bio (UPB) Projected to Post Earnings on Thursday - Defense World
Upstream Bio (NASDAQ:UPB) Sets New 52-Week Low – Time to Sell? - Defense World
Upstream Bio (NASDAQ:UPB) Trading Down 3.9%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 52-Week LowTime to Sell? - MarketBeat
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Upstream Bio (NASDAQ:UPB) Trading Down 10.4%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 1-Year LowWhat's Next? - MarketBeat
Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz
Upstream Bio (NASDAQ:UPB) Stock Price Down 7%What's Next? - MarketBeat
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Upstream Bio (NASDAQ:UPB) Trading Up 8.5%Here's Why - MarketBeat
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Single-use Bioprocessing Market Size to Hit USD 146.84 Bn by 2034 - Precedence Research
Upstream Bio (NASDAQ:UPB) Trading Down 3%Here's What Happened - MarketBeat
Upstream Bio (NASDAQ:UPB) Shares Up 5.7%Time to Buy? - MarketBeat
Should You Scoop Up This 'Strong Buy' Biotech Before December 23? - MSN
Amgen Inc (AMGN-Q) QuotePress Release - The Globe and Mail
Newly Public Biotech Startup Hires Life Sciences Veteran as GC - Law.com
Upstream Bio (NASDAQ:UPB) Shares Gap DownWhat's Next? - MarketBeat
Upstream Bio Appoints Allison Ambrose as General Counsel - citybiz
Upstream Bio (NASDAQ:UPB) Shares Down 5%Time to Sell? - MarketBeat
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation (UPB) - Seeking Alpha
Upstream Bio To Be Added To Russell 2000 - MENAFN.COM
Upstream Bio to be Added to Russell 2000 - Baystreet.ca
Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewswire
Upstream Bio to Join Russell 2000® Index, Gaining Access to $10.5T Benchmark-Linked Assets - StockTitan
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):